This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fuster, V. Articles by Farkouh, M. E. Search for Related Content PubMed PubMed Citation Articles by Fuster, V. Articles by Farkouh, M. E. Related Collections Type 1 diabetes Type 2 diabetes Acute coronary syndromes

(Circulation. 2008;118:1607-1608.)
© 2008 American Heart Association, Inc.

Editorial

Acute Coronary Syndromes and Diabetes Mellitus

A Winning Ticket for Prasugrel

Valentin Fuster, MD, PhD; Michael E. Farkouh, MD, MSc

From the Mount Sinai School of Medicine, Mount Sinai Hospital, New York, NY.

Correspondence to Valentin Fuster, MD, PhD, Mount Sinai School of Medicine, Mount Sinai Hospital, 1 Gustave L. Levy Pl, Box 1030, New York, NY 10029–6574. E-mail valentin.fuster@mssm.edu

Key Words: Editorials • coronary disease • diabetes mellitus • myocardial infarction • platelets • thrombosis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Numerous trials have demonstrated a worse outcome for diabetic patients with acute coronary syndromes (ACS) compared with their nondiabetic counterparts.¹ Because our knowledge of the influence of diabetes mellitus on ACS outcomes is based on subgroup analyses of randomized trials that are often post hoc and underpowered, most clinicians have not entertained the concept that we might consider approaching the diabetic patient differently. ACS trials, from the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial to the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial, have suggested that whereas diabetic patients may have a higher event rate, the relative risk with the use of the conventional antithrombotic therapies is comparable to that observed in the nondiabetic cohort.

Article p 1626

Numerous mechanisms may explain this increased risk. Diabetic patients are more likely to have other comorbidities, such as renal insufficiency and hypertension, that lead to worse outcomes. Diabetic patients often have early signs of heart failure, particularly diastolic heart failure, which can lead to increasing morbidity and mortality.² Perhaps the most important difference is that type 2 diabetes mellitus is associated with a proinflammatory and a prothrombotic state.^3,4 Of interest, in the insulin-resistant state, perhaps through glycosylation, an upregulation of platelet membrane proteins such as the P2Y₁₂ receptor/pathway takes place, which is the target of the active metabolite of clopidogrel.⁵ Thus, treatment with insulin may identify a group of subjects at particular risk for poor response to platelet inhibitors such as clopidogrel. Furthermore, glycosylation . . . [Full Text of this Article]

This article has been cited by other articles:

				Antiplatelet Therapy for Patients with Diabetes: More Is Better Journal Watch Cardiology, December 3, 2008; 2008(1203): 6 - 6. [Full Text]